Blueprint Medicines Corp. (BPMC)
NASDAQ (NGS) NASDAQ (NGS) Primary 
The Schall Law Firm Notifies Investors Of Blueprint Medicines Corporation About Ongoing Investigations Into Potential Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors Of Blueprint Medicines Corporation Are Informed By The Schall Law Firm About Ongoing Investigations Into Possible Securities Law Breaches
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Reminds Shareholders of an Investigation into Blueprint Medicines Corporation (BPMC) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Blueprint Medicines Corporation ("Blueprint ") (NASDAQ:BPMC) concerning possible violations of federal securities laws. Blueprint announced top-line results from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib) on August 17, 2022.
Shareholders that lost money on Blueprint Medicines Corporation(BPMC) should contact Levi & Korsinsky about Securities Fraud Investigation - BPMC
NEW YORK, NY / ACCESSWIRE / August 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Blueprint Medicines Corporation ("Blueprint ") (NASDAQ:BPMC) concerning possible violations of federal securities laws. Blueprint announced top-line results from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib) on August 17, 2022.
Investors Of Blueprint Medicines Corporation Are Notified By The Schall Law Firm Regarding Ongoing Investigations Into Potential Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Blueprint Medicines (BPMC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Blueprint Medicines (BPMC), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Levi & Korsinsky Reminds Shareholders of an Investigation into Blueprint Medicines Corporation (BPMC) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Blueprint Medicines Corporation ("Blueprint ") (NASDAQ:BPMC) concerning possible violations of federal securities laws. Blueprint announced top-line results from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib) on August 17, 2022.
Investors Of Blueprint Medicines Corporation Are Alerted By The Schall Law Firm About Continuing Probes Into Possible Securities Law Breaches
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Potential Securities Law Violations
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Reminds Shareholders of an Investigation into Blueprint Medicines Corporation (BPMC) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Blueprint Medicines Corporation ("Blueprint ") (NASDAQ:BPMC) concerning possible violations of federal securities laws. Blueprint announced top-line results from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib) on August 17, 2022.
Blueprint Medicines Corporation Investors Are Informed By The Schall Law Firm Of Current Investigations Into Potential Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat
Blueprint Medicines' (BPMC) earnings and revenues surpass estimates in the second quarter of 2024. The company raises its product revenue guidance for 2024.
